参考文献/References:
[1]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344. [2]Banerjee A,Singh J.Remodeling adipose tissue inflammasome for type 2 diabetes mellitus treatment:Current perspective and translational strategies[J].Bioeng Transl Med,2019,5(2):e10150. [3]Laakso M.Biomarkers for type 2 diabetes[J].Mol Metab,2019,27S(Suppl):S139-S146. [4]de Gonzalo-Calvo D,Kenneweg F,Bang C,et al.Circulating Long Noncoding RNAs in Personalized Medicine:Response to Pioglitazone Therapy in Type 2 Diabetes[J].J Am Coll Cardiol,68(25):2914-2916. [5]Leung A,Natarajan R.Long Noncoding RNAs in Diabetes and Diabetic Complications[J].Antioxid Redox Signal,2018,29(11):1064-1073. [6]Chihara A,Tanaka A,Morimoto T,et al.Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy:a secondary analysis of the REASON trial[J].Cardiovasc Diabetol,2019,18(1):158. [7]Feng T,Li K,Zheng P,et al.Weighted Gene Coexpression Network Analysis Identified MicroRNA Coexpression Modules and Related Pathways in Type 2 Diabetes Mellitus[J].Oxid Med Cell Longev,2019(2019):9567641. [8]Zhang L,Li R,He J,et al.Co-expression analysis among microRNAs,long non-coding RNAs,and messenger RNAs to understand the pathogenesis and progression of diabetic kidney disease at the genetic level[J].Methods,2017(124):46-56. [9]Sathishkumar C,Prabu P,Mohan V,et al.Linking a role of lncRNAs(long non-coding RNAs)with insulin resistance,accelerated senescence,and inflammation in patients with type 2 diabetes[J].Hum Genomics,2018,12(1):41. [10]Goyal N,Kesharwani D,Datta M.Lnc-ing non-coding RNAs with metabolism and diabetes:roles of lncRNAs[J].Cell Mol Life Sci,2018,75(10):1827-1837. [11]Shaker OG,Abdelaleem OO,Mahmoud RH,et al.Diagnostic and prognostic role of serum miR-20b,miR-17-3p,HOTAIR,and MALAT1 in diabetic retinopathy[J].IUBMB Life,2019,71(3):310-320. [12]Xia C,Liang S,He Z,et al.Metformin,a first-line drug for type 2 diabetes mellitus,disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells[J].Eur J Pharmacol,2018(830):59-67. [13]Wang XM,Li XM,Song N,et al.Long non-coding RNAs H19,MALAT1 and MIAT as potential novel biomarkers for diagnosis of acute myocardial infarction[J].Biomed Pharmacother,2019(118):109208. [14]Sun G,Li Y,Ji Z.Up-regulation of MIAT aggravates the atherosclerotic damage in atherosclerosis mice through the activation of PI3K/Akt signaling pathway[J].Drug Deliv,2019,26(1):641-649. [15]Yan B,Tao ZF,Li XM,et al.Aberrant expression of long noncoding RNAs in early diabetic retinopathy[J].Invest Ophthalmol Vis Sci,2014,55(2):941-951.
相似文献/References:
[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in
Patients with Type 2 Diabetes Mellitus[J].Medical Information,2018,31(12):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Medical Information,2018,31(12):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的
相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2018,31(12):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,31(12):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Medical Information,2018,31(12):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2022,35(12):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[7]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Medical Information,2022,35(12):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[8]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Medical Information,2022,35(12):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[9]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Medical Information,2022,35(12):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[10]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行
健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Medical Information,2018,31(12):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]